Compare Haedal Protocol (HAEDAL) vs Enzyme (MLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haedal Protocol vs Enzyme — how do they compare? Haedal Protocol trades at Rp293.03 (market cap Rp141,55M, Rp30,26M 24h volume), while Enzyme trades at Rp30,212 (market cap Rp134,13M, Rp104,56M 24h volume). The key difference: Haedal Protocol and Enzyme are close in size by market cap, and Haedal Protocol's supply is capped (483,3M / 1B HAEDAL (49%)) while Enzyme's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Haedal Protocol for 15 Days and Enzyme for 29 Days on average.
| HAEDAL | MLN | |
|---|---|---|
Market Cap | Rp141,55M | Rp134,13M |
Volume (24h) | Rp30,26M | Rp104,56M |
Circulating Supply | 483,3M / 1B HAEDAL (49%) | 3,3M MLN |
Typical Hold Time | 15 Days | 29 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Haedal Protocol currently trades at Rp288.18 with a market cap of Rp139.43M, showing bearish technical signals from moving averages while oscillators remain neutral. The token has 49% circulating supply with an average hold time of 15 days. Current price sits near the pivot point of Rp288, with immediate support at Rp283 and resistance at Rp292. No major protocol updates or ecosystem developments were identified in recent analysis.
Overall outlook remains cautious with bearish technical momentum outweighing neutral oscillators. Key opportunity lies in potential bounce from support levels, while major risks include low liquidity and limited market depth. Investors should monitor for any protocol developments that could drive adoption.
Enzyme (MLN) shows limited market activity with a modest market cap of Rp134,13M and circulating supply of 3,3jt tokens. The asset demonstrates relatively low volatility with an average hold time of 29 days, suggesting stable holder behavior. Trading volumes appear subdued across exchanges, indicating limited speculative interest. No significant protocol upgrades or ecosystem developments have been reported recently, though the project continues to operate its decentralized asset management platform.
Overall outlook remains cautious due to limited liquidity and trading activity. Key opportunities include potential ecosystem growth in decentralized finance asset management, while major risks include low market depth, regulatory uncertainty for DeFi protocols, and competition from larger DeFi platforms. The token's utility within its native protocol remains its primary value driver.
About Haedal Protocol
Haedal is a leading liquid staking protocol built specifically on the Sui blockchain. It provides a reliable infrastructure that enables users to stake their SUI and Walrus tokens with validators, allowing them to earn ongoing consensus rewards. Additionally, users can unlock liquidity in the form of liquid staking tokens (LST), which can be utilized across decentralized finance (DeFi) applications. Haedal's goal is to become the primary platform for staking and earning within the Sui ecosystem.
Read more on HAEDAL →About Enzyme
Enzyme is an easy-to-use on-chain asset management system that enables access to digital assets and DeFi from one simple, unified app. It provides a front-to-back execution and order management system, which provides fully automated reporting, risk management, administration, governance and operations.
Read more on MLN →
